Related Experiment Video
Updated: Jan 4, 2026

A Reporter Based Cellular Assay for Monitoring Splicing Efficiency
Published on: September 15, 2021
Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma
Hiromichi Suzuki1,2, Sachin A Kumar1,2,3, Shimin Shuai4,5
1The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.
Abstract:
In cancer, recurrent somatic single-nucleotide variants-which are rare in most paediatric cancers-are confined largely to protein-coding genes1-3. Here we report highly recurrent hotspot mutations (r.3A>G) of U1 spliceosomal small nuclear RNAs (snRNAs) in about 50% of Sonic hedgehog (SHH) medulloblastomas. These mutations were not present across other subgroups of medulloblastoma, and we identified these hotspot mutations in U1 snRNA in only <0.1% of 2,442 cancers, across 36 other tumour types. The mutations occur in 97% of adults (subtype SHHδ) and 25% of adolescents (subtype SHHα) with SHH medulloblastoma, but are largely absent from SHH medulloblastoma in infants. The U1 snRNA mutations occur in the 5' splice-site binding region, and snRNA-mutant tumours have significantly disrupted RNA splicing and an excess of 5' cryptic splicing events. Alternative splicing mediated by mutant U1 snRNA inactivates tumour-suppressor genes (PTCH1) and activates oncogenes (GLI2 and CCND2), and represents a target for therapy. These U1 snRNA mutations provide an example of highly recurrent and tissue-specific mutations of a non-protein-coding gene in cancer.
Insights
Highly recurrent U1 spliceosomal small nuclear RNA (snRNA) mutations drive Sonic hedgehog medulloblastomas. These non-coding RNA mutations disrupt splicing, impacting oncogenes and tumor suppressors, offering a potential therapeutic target.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Recurrent somatic variants in cancer are typically rare in pediatric cancers and primarily affect protein-coding genes.
- U1 spliceosomal small nuclear RNAs (snRNAs) are crucial components of the spliceosome, involved in RNA splicing.
Purpose of the Study:
- To investigate the role of mutations in non-coding genes, specifically U1 snRNAs, in paediatric cancers.
- To identify recurrent mutations in U1 snRNAs within specific medulloblastoma subgroups.
Main Methods:
- Whole-exome sequencing and variant analysis of medulloblastoma samples.
- RNA sequencing to assess splicing patterns and identify cryptic splicing events.
- Analysis of mutation frequency across different cancer types and patient demographics.
Main Results:
- Discovery of highly recurrent hotspot mutations (r.3A>G) in U1 snRNA in approximately 50% of Sonic hedgehog (SHH) medulloblastomas.
- These U1 snRNA mutations were found in 97% of adult and 25% of adolescent SHH medulloblastomas, but rarely in infant cases or other cancer types (<0.1%).
- Mutations in U1 snRNA lead to disrupted RNA splicing, increased 5' cryptic splicing, inactivation of tumor suppressors (PTCH1), and activation of oncogenes (GLI2, CCND2).
Conclusions:
- U1 snRNA mutations represent a novel class of highly recurrent, tissue-specific mutations in a non-coding gene in cancer.
- These mutations significantly alter gene expression through aberrant splicing, driving SHH medulloblastoma development.
- Targeting the alternative splicing mediated by mutant U1 snRNA presents a potential therapeutic strategy for SHH medulloblastomas.
Related Concept Videos
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Alternative RNA Splicing
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon...
RNA Splicing
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Nonsense-mediated mRNA Decay

